The 2 most recent market catalysts affecting $TRNS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Transcat Announces Acquisition Of Southeastern Biomedical Associates For $12.8M In Cash, Effective August 31
This acquisition is a positive development for Transcat, as it directly expands their service capabilities in the biomedical sector and strengthens their presence in the Southeaste…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Transcat Q1 Adj. EPS $0.51 Beats $0.38 Estimate, Sales $92.945M Beat $86.546M Estimate
Transcat (TRNS) announced its Q1 earnings, reporting adjusted EPS of $0.51, which comfortably surpassed the analyst consensus of $0.38. This 34.21% beat on the bottom line, despite…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.